Back to results

The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork

Primary Purpose

Open-angle Glaucoma

Status

Completed

Phase

Not Applicable

Locations

China

Study Type

Interventional

Intervention

trabeculectomy

About this trial

This is an interventional basic science trial for Open-angle Glaucoma focused on measuring matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3, calcium-sensing receptor, trabecular meshwork, open-angle glaucoma

Eligibility Criteria

50 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

intraocular pressure greater than 22 mmHg with two or more medications
wide anterior chamber angle
glaucomatous optic neuropathy (Glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect
visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry

Exclusion Criteria:

the presence of any secondary form of glaucoma including exfoliation syndrome or a history of ocular trauma, etc

Sites / Locations

Tianjin Medical University Eye Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

trabeculectomy

Arm Description

Outcomes

Primary Outcome Measures

the expressions of matrix metalloproteinase 13 and calcium-sensing receptor

Secondary Outcome Measures

histological changes of trabecular meshwork

Full Information

NCT ID

NCT02638181

First Posted

December 14, 2015

Last Updated

January 8, 2017

Sponsor

Lv Yingjuan

1. Study Identification

Unique Protocol Identification Number

NCT02638181

Brief Title

The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork

Official Title

The Expression of Matrix Metalloproteinase 13（MMP13）, Tissue Inhibitor of Metalloproteinases 3（TIMP13）, and Calcium-sensing Receptor（CaSR） in Human Trabecular Meshwork

Study Type

Interventional

2. Study Status

Record Verification Date

January 2017

Overall Recruitment Status

Completed

Study Start Date

July 2013 (undefined)

Primary Completion Date

December 2015 (Actual)

Study Completion Date

December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor-Investigator

Name of the Sponsor

Lv Yingjuan

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This study was to assess the distinct expression of matrix metalloproteinase 13,tissue inhibitor of metalloproteinases 3, and calcium-sensing receptor, in human trabecular meshwork between normal and glaucomatous eyes.The expressions of matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3 and calcium-sensing receptor in the trabecular meshwork tissues were examined by streptavidin-peroxidase immunohistochemical staining method and western blot, and histological changes of trabecular meshwork were studied by Hematoxylin and Eosin staining.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Open-angle Glaucoma

Keywords

matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3, calcium-sensing receptor, trabecular meshwork, open-angle glaucoma

7. Study Design

Primary Purpose

Basic Science

Study Phase

Not Applicable

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

60 (Actual)

8. Arms, Groups, and Interventions

Arm Title

trabeculectomy

Arm Type

Experimental

Intervention Type

Procedure

Intervention Name(s)

trabeculectomy

Primary Outcome Measure Information:

Title

the expressions of matrix metalloproteinase 13 and calcium-sensing receptor

Time Frame

one hour after operation

Secondary Outcome Measure Information:

Title

histological changes of trabecular meshwork

Time Frame

one hour after operation

10. Eligibility

Sex

All

Minimum Age & Unit of Time

50 Years

Maximum Age & Unit of Time

75 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: intraocular pressure greater than 22 mmHg with two or more medications wide anterior chamber angle glaucomatous optic neuropathy (Glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry Exclusion Criteria: the presence of any secondary form of glaucoma including exfoliation syndrome or a history of ocular trauma, etc

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

xiaorong li

Organizational Affiliation

Tianjin Medical University Eye Hospital

Official's Role

Study Director

Facility Information:

Facility Name

Tianjin Medical University Eye Hospital

City

Tianjin

State/Province

Tianjin

ZIP/Postal Code

300384

Country

China

12. IPD Sharing Statement

Learn more about this trial

The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork

We'll reach out to this number within 24 hrs